Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Guttman-Yassky Emma; Brunner Patrick M.; Neumann Avidan U.; Khattri Saakshi; Pavel Ana B.; Malik Kunal; Singer Giselle K.; Baum Danielle; Gilleaudeau Patricia; Sullivan-Whalen Mary; Rose Sharon; On Shelbi Jim; Li Xuan; Fuentes-Duculan Judilyn; Estrada Yeriel; Garcet Sandra; Traidl-Hoffmann Claudia; Krueger James G.; Lebwohl Mark G.

首页> 外文期刊>Journal of the American Academy of Dermatology >Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

【24h】

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

机译：Fezakinumab（IL-22单克隆抗体）在成人中具有中度至重度的特征性皮炎的疗效和安全性因常规治疗不足：随机，双盲，相2A试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: Interleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function.

机译：背景：白细胞介素22促进表皮增生并抑制皮肤屏障功能。

著录项

来源
《Journal of the American Academy of Dermatology》 |2018年第5期|共16页
作者
Guttman-Yassky Emma; Brunner Patrick M.; Neumann Avidan U.; Khattri Saakshi; Pavel Ana B.; Malik Kunal; Singer Giselle K.; Baum Danielle; Gilleaudeau Patricia; Sullivan-Whalen Mary; Rose Sharon; On Shelbi Jim; Li Xuan; Fuentes-Duculan Judilyn; Estrada Yeriel; Garcet Sandra; Traidl-Hoffmann Claudia; Krueger James G.; Lebwohl Mark G.;
展开▼
作者单位

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Rockefeller Univ Lab Invest Dermatol 1230 York Ave New York NY 10021 USA;

Tech Univ Munich Univ Ctr Hlth Sci Inst Environm Med Klinikum Augsburg Augsburg Germany;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Rockefeller Univ Lab Invest Dermatol 1230 York Ave New York NY 10021 USA;

Rockefeller Univ Lab Invest Dermatol 1230 York Ave New York NY 10021 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Rockefeller Univ Lab Invest Dermatol 1230 York Ave New York NY 10021 USA;

Rockefeller Univ Lab Invest Dermatol 1230 York Ave New York NY 10021 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Rockefeller Univ Lab Invest Dermatol 1230 York Ave New York NY 10021 USA;

Tech Univ Munich Univ Ctr Hlth Sci Inst Environm Med Klinikum Augsburg Augsburg Germany;

Rockefeller Univ Lab Invest Dermatol 1230 York Ave New York NY 10021 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词
atopic dermatitis; fezakinumab; IL-22; placebo-controlled trial; moderate-to-severe AD;

机译：特应性皮炎;Fezakinumab;IL-22;安慰剂对照试验;中度至严重的广告;

相似文献

外文文献
中文文献

1. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial [J] . Guttman-Yassky Emma, Brunner Patrick M., Neumann Avidan U., Journal of the American Academy of Dermatology . 2018,第5期

机译：Fezakinumab（IL-22单克隆抗体）在成人中具有中度至重度的特征性皮炎的疗效和安全性因常规治疗不足：随机，双盲，相2A试验
2. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial [J] . Thaci Diamant, Simpson Eric L., Beck Lisa A., The Lancet . 2016,第10013期

机译：局部治疗不足以控制中度至重度特应性皮炎的成人dupilumab的疗效和安全性：一项随机，安慰剂对照，剂量范围为2b的试验
3. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial [J] . Thaci Diamant, Simpson Eric L., Beck Lisa A., The Lancet . 2016,第10013期

机译：局部治疗不足以控制中度至重度特应性皮炎的成人dupilumab的疗效和安全性：一项随机，安慰剂对照，剂量范围为2b的试验
4. A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008-2011 update [C] . Thierry Olivry, Petra Bizikova World Congress of Veterinary Dermatology . 2013

机译：对狗的预防或治疗特应性皮炎的随机对照试验进行系统综述：2008-2011更新
5. Topical Probiotics in the Treatment of Atopic Dermatitis: A Randomized Controlled Trial [D] . Chen, Jessica. 2018

机译：局部益生菌治疗特应性皮炎：随机对照试验
6. Extended report: Efficacy and safety of tabalumab an anti-BAFF monoclonal antibody in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised double-blind placebo-controlled phase 3 study [O] . Michael Schiff, Bernard Combe, Thomas Dörner, 2015

机译：扩展报告：抗BAFF单克隆抗体塔巴木单抗对中度至重度类风湿性关节炎和对TNF抑制剂反应不足的患者的疗效和安全性：一项随机双盲安慰剂对照3期研究的结果
7. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids:A randomized, placebo-controlled phase II trial (TREBLE) [O] . Simpson, Eric L., Flohr, Carsten, Eichenfield, Lawrence F., 2019

机译：Lebrikizumab（抗IL-13单克隆抗体）在局部至局部皮质类固醇激素控制不充分的中度至重度特应性皮炎成人中的疗效和安全性：一项随机，安慰剂对照的II期临床试验（TREBLE）

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅